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Abstract 
Background: Depression is highly underdiagnosed in primary care settings in Latvia. Screening for depression in 
primary care is potentially an efficient way to find undetected case s and improve diagnostics. We aimed to validate 
both a nine-item and two-item Patient Health Questionnaire (PHQ-9 and PHQ-2) in the Latvian and Russian languages 
in primary care settings using a representative sample in Latvia.
Materials and methods: The study was carried out within the framework of the National Research Program BIO-
MEDICINE to assess the prevalence of mental disorders at 24 primary care facilities. During a 1-week period, all consec-
utive adult patients were invited to complete the PHQ-9 and PHQ-2. Criterion validity was assessed against the Mini 
International Neuropsychiatric Interview (MINI).
Results: There were 1467 patients who completed the PHQ-9 and the MINI. Overall, the PHQ-9 items showed good 
internal reliability (Cronbach’s alpha 0.81 for Latvian version and 0.79 for Russian version of the PHQ-9). A cut-off score 
of 8 or greater was established for the PHQ-9 (sensitivity 0.75 and 0.79, specificity 0.84 and 0.80 for Latvian and Russian 
languages, respectively). For the PHQ-2, a score of 2 or higher (sensitivity 0.79 and 0.79, specificity 0.65 and 0.67 for 
Latvian and Russian languages) detected more cases of depression than a score of 3 or higher.
Conclusions: We suggest GPs ask patients to respond to the first 2 questions of the PHQ-9. If their score is positive, 
the patients should then complete the PHQ-9.
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Background
Depression is a common psychiatric condition that has 
widespread consequences both at the individual and soci-
etal level. It is among the leading non-fatal diseases glob-
ally [1]. Long term consequences of depression include 
reduced quality of life, risk of suicide, increased rates of 
hospital admission, increased risk for chronical medical 
conditions and stigmatization [2–5].
The WHO study on psychological problems in general 
health care across 14 countries found that 14% of indi-
viduals suffered from major depression [6]. Despite the 
fact that most care for depression is delivered by general 
practitioners, under-recognition of depression has been 
extensively described [7]. Depression is often under-
detected in primary care: approximately 50% of GPs cor-
rectly identify depression cases, and even fewer, 34%, 
record it in their notes [8].
Despite rich data from studies of depression in primary 
care in Western Europe [9, 10], there still is a need for 
studies from Eastern Europe [11]. The best available data 
suggest that under-diagnosis of depression is particu-
larly salient for Latvia, where the 12-month prevalence of 
depression has been estimated at 7.8%, but according to 
the data from the Latvian National Health Service, only 
4423 unique patients have been diagnosed with a mood 
disorder by general practitioners (GPs) [12, 13].
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Because of large estimates of underdiagnosed and 
undertreated depression in primary care, improved 
screening could reduce the burden of depression. Rou-
tine primary care screening can facilitate improvement of 
the diagnosis rates of adult depression and has been rec-
ommended by the US Preventive Services Task Force [14, 
15]. However, it is notable that some national guidelines 
doubt the effectiveness of screening for depression [16].
It is essential that depression screening tools are reli-
able and valid to ensure that the results they generate 
are clinically correct [17]. There are numerous studies 
assessing the reliability and validity of depression screen-
ing tools, but there is currently no consensus on one par-
ticular screening tool to be used for depression screening 
across primary healthcare settings [18]. Moreover, to be 
acceptable in practice, it is essential that instruments are 
easy and quick to use [19].
The Patient Health Questionnaire-9 (PHQ-9) was 
developed as a depression screener for depression in 
primary care. The PHQ-9 is a self-rating instrument for 
depression developed in the late 1990s from the Primary 
Care Evaluation of Mental Disorders (PRIME-MD) [20] 
and based on the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM-IV) criteria for 
MDD [21]. This tool consisting of 9 items is known for 
its ease of completion for the patient, ease of scoring and 
interpretation, and public availability. It is used among 
racially and ethnically diverse populations. Respond-
ents rate the scale items from 0 to 3 according to the 
frequency of their experience over the previous 2-week 
period (not at all, several days, more than half the days, 
or nearly every day). A cut-off score of ≥ 10 has been rec-
ommended for detecting cases of major depressive disor-
der (MDE) [21, 22]. Over 100 studies have examined the 
PHQ-9 in primary care [22]. Moreover, the PHQ-9 has 
been validated in medical populations [23–25], general 
populations [26–29] and psychiatric samples [30–34].
Of recent interest has been the use of fewer screen-
ing questions from the PHQ–9 [35, 36]. The PHQ-2 was 
developed for depression screening, with some evidence 
for a role in diagnosing depression [35, 37, 38]. These 2 
questions, collectively known as the PHQ-2, ask about 
the frequency of the symptoms of depressed mood and 
anhedonia, scoring each as 0 (not at all) to 3 (nearly every 
day). The validation study of the PHQ-2 by Kroenke et al. 
included a sample of 580 primary care patients [35].
A valid depression screener in Latvian and Russian is 
important for Latvia because 61.8% of the population is 
Latvian, with the remainder being people from Russian 
language-speaking nations (Russia, Belarus, and Ukraine) 
[39, 40].
The aim of our study was to validate the PHQ-9 and 
PHQ-2 in Latvian and Russian languages using the Mini 
International Neuropsychiatric Interview (MINI) as 
the reference standard in a representative primary care 
sample.
Materials and methods
The current study was carried out in 2015 within the 
framework of the National Research Program, BIOMED-
ICINE 2014–2017, a cross-sectional study to assess the 
prevalence of mental disorders in primary care settings in 
Latvia. The study recruited patients from 24 primary care 
facilities all over the country that covered all regions of 
Latvia. The survey was conducted in the two most com-
monly spoken languages in Latvia (Latvian and Russian). 
The programme was financed by the Latvian Ministry of 
Education and Science. The main aim of this programme 
is to develop new prevention, treatment, and diagnostic 
methods and practices, as well as biomedical technolo-
gies to improve public health in Latvia. The programme 
has existed since 2007 and comprises certain areas: car-
diovascular and metabolic diseases, oncological diseases, 
and childhood and infectious diseases. Mental health was 
included in the programme for the first time.
During a 1-week period in each GP’s facility, all con-
secutive patients aged 18 years or older visiting a primary 
care physician with any health concerns were invited to 
participate in the study. Those who visited their GP for 
any administrative reasons were not included in the sam-
ple. No further restrictions on patient selection were 
implemented.
All consecutive patients were invited to complete the 
paper-and-pencil form of the PHQ-9 in the preferred lan-
guage (Latvian or Russian) before seeing the GP, followed 
by interview with a structured socio-demographic ques-
tionnaire. All uncertainties and questions raised were 
explained by a psychiatrist. Both versions of the PHQ-9 
in Latvia have been previously adapted and used in a 
nationwide general population study [41]. However, at 
that time, no cut-off score for Latvia was established, and 
a cut-off score ≥ 10 has been applied as recommended 
by Kroenke et  al. [21]. In 2014, within the pilot project 
of the National Research Programme, BIOMEDICINE, 
that was conducted at 6 primary care facilities, the cut-
off score of the PHQ-9 of ≥ 10 for both languages was 
established [42]. However, that study included validation 
of the PHQ-9 and not the PHQ-2 and had considerable 
limitations such as a small sample size that was not rep-
resentative of the primary care population nationwide.
No more than 2  weeks after completing the PHQ-9, 
four psychiatrists who were blind to the PHQ-9 scores 
interviewed the respondents over the phone with the 
Mini International Neuropsychiatric Interview (MINI), 
Version 6.0.0. The MINI is a structured diagnostic 
interview that was validated by convergence with the 
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Structured Clinical Interview for the DSM-III-R Patient 
Version (SCID-P) and the Composite International 
Diagnostic Interview (CIDI) and by expert professional 
opinion [43]. The good psychometric characteristics 
of the MINI, its ability to be administered rapidly, and 
its acceptability to patients made it a good choice for 
research purposes [44]. The MINI has been translated 
and adapted for both Latvian and Russian languages by 
the authorship holders and previously has been used in 
population-based study [13]. The MINI was used as the 
standard to determine the presence of major depressive 
episodes and was conducted over the telephone. Admin-
istering the MINI over the telephone is acceptable and 
was applied in other studies [45, 46]. In this study, all 
modules of the MINI were used. Participants diagnosed 
with depression or suicide ideations or attempt were 
referred for appropriate care.
This study was approved by the Ethics Committee of 
the Riga Stradins University, Riga, Latvia. The project 
was conducted in accordance with the Declaration of 
Helsinki and its subsequent amendments. All patients 
were enrolled after providing written informed consent. 
Neither participating family practices nor patients were 
compensated for their participation.
Statistical analysis
The internal reliability of the PHQ-9 was assessed by 
Cronbach’s alpha coefficient. The criterion validity of the 
PHQ-9 and the PHQ-2 was assessed by receiver operat-
ing characteristic (ROC) analysis. The criterion validity 
of the PHQ-9 and the PHQ-2 was analysed in terms of 
sensitivity, specificity, and positive and negative predic-
tive values for different cut-off scores. The Latvian and 
Russian versions of the MINI, which is used to diagnose 
major depressive disorder, were used as the criterion 
standard. Data analyses were performed in Stata version 
14 (Stata Corp). A separate analysis was conducted for 
the Latvian and Russian languages.
Results
In total, 1604 patients were invited to complete the 
PHQ-9 scale, and 1585 of them completed the PHQ-
9. From those who completed the PHQ-9, 100 patients 
did not answer a telephone call three times and were 
excluded, and 1485 patients were interviewed with the 
MINI over the telephone. In the final analysis, 1467 
patients (448 men and 1019 women) were included. The 
questionnaires of 18 patients had to be dropped out due 
to insufficient data quality.
The main characteristics of those who were included 
in the analysis are shown in Table 1. For both languages, 
a separate analysis was applied. According to the MINI, 
10.2% (95% CI 8.7–11.8) of the whole population had 
current depression and 28.1% (95% CI 25.9–30.4) had 
experienced at least one depressive episode in the past. 
Current depression was found in 8.7% of those who 
completed the PHQ-9 in Latvian and 12.3% in Russian. 
The reliability (Cronbach’s alpha) for the Latvian version 
of the PHQ-9 scale was 0.82 and 0.79 for the Russian 
version.
The performance of the PHQ-9 was compared against 
the diagnosis of major depression as determined by the 
MINI, a reliable standard. The sensitivity, specificity, and 
likelihood ratio are presented separately for the Latvian 
and Russian languages in Tables 2 and 3, respectively. At 
a cut-off score of 8 or above, the sensitivity of the Latvian 
version of the PHQ-9 was 0.75, and the specificity was 
0.84. For the Russian version of the PHQ-9, they were 
0.79 and 0.80, respectively. The positive likelihood ratio 
was 4.57 for the Latvian version and 4.0 for the Russian 
version at this cut-off score. A cut-off score of 10 for the 
PHQ-9 Latvian language decreased sensitivity to 60.8% 
and increased specificity to 91.1%. A cut-off score of 10 
for the PHQ-9 Russian language decreased sensitivity 
to 67.7% and increased specificity to 89.7%. The cut-offs 
chosen in the ROC curve analysis where the ones closer 
is to the upper left corner. ROC curve analysis (Figs.  1, 
2) supported the criterion validity of the PHQ-9 in 
Table 1 Characteristics of the total sample (n = 1467)
Latvian Russian
% (n) % (n)
Total 100 (912) 100 (555)
Lifetime depression 27.6 (252) 28.7 (159)
Past only depression 19.0 (173) 16.4 (91)
Current depression 8.7 (79) 12.3 (68)
Gender
Male 30.7 (280) 30.3 (168)
Female 69.3 (632) 69.7 (387)
Age groups
18–34 17.7 (161) 8.7 (48)
35–54 30.6 (279) 31.7 (176)
55–64 22.3 (203) 26.3 (146)
65+ 29.5 (269) 33.3 (185)
Education
Primary or less 16.2 (148) 15.4 (78)
Secondary 53.4 (487) 54.3 (310)
Higher than secondary 29.8 (272) 29.7 (164)
No answer 0.6 (5) 0.6 (3)
Socioeconomic status
Above average 5.2 (47) 4.3 (24)
Average 71.3 (650) 60.9 (338)
Below average 23.5 (214) 34.8 (193)
No answer 0.1 (1) 0.0 (0)
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differentiating between patients with and without major 
depression (AUC = 0.86 for Latvian version and 0.88 for 
Russian version).
We also performed validity analysis for both languages 
of the PHQ-2 against the MINI The sensitivity, specific-
ity, LR+ and LR− for all possible PHQ-2 thresholds for 
both Latvian and Russian languages are presented in 
Tables 4 and 5. At the threshold ≥ 2, the PHQ-2 Latvian 
version correctly identified 78.5% of MINI cases (sensi-
tivity) and 64.6% of non-cases of depression (specificity). 
Table 2 Sensitivity, specificity, and  likelihood ratios 
at various cut-off points of the Latvian version of the PHQ-9







≥ 6 82.3 69.6 70.7 2.71 0.25
≥ 7 77.2 77.3 77.3 3.40 0.29
≥ 8 74.7 83.7 82.9 4.57 0.30
≥ 9 70.9 87.9 86.4 5.84 0.33
≥ 10 60.8 91.1 88.5 6.84 0.43
≥ 11 55.7 94.1 90.8 9.47 0.47
≥ 12 49.4 95.8 91.8 11.75 0.53
≥ 13 44.3 97.4 92.8 16.78 0.57
≥ 14 36.7 98.2 92.9 20.39 0.64
Table 3 Sensitivity, specificity, and  likelihood ratios 
at various cut-off points of the Russian version of the PHQ-9







≥ 6 92.7 64.2 67.8 2.59 0.11
≥ 7 86.8 73.5 75.1 3.28 0.18
≥ 8 79.4 80.1 80.0 4.00 0.26
≥ 9 67.7 85.4 83.2 4.64 0.38
≥ 10 67.7 89.7 87.0 6.59 0.36
≥ 11 58.8 92.0 87.9 7.34 0.45
≥ 12 52.9 93.8 88.8 8.59 0.50
≥ 13 45.6 95.9 89.7 11.10 0.57
≥ 14 35.2 96.3 88.8 9.55 0.67
Fig. 1 The receiver operating characteristic (ROC) curve of the 
Latvian version of the PHQ-9 versus the MINI for the major depression 
diagnosis
Fig. 2 The receiver operating characteristic (ROC) curve of the 
Russian version of the PHQ-9 versus the MINI for the major depression 
diagnosis
Table 4 Sensitivity, specificity, and  likelihood ratios 
at various cut-off points of the Latvian version of the PHQ-2







≥ 1 89.9 40.7 45.0 1.52 0.25
≥ 2 78.5 64.6 65.8 2.22 0.33
≥ 3 55.7 89.9 87.0 5.52 0.49
≥ 4 36.00 94.2 89.4 6.59 0.66
≥ 5 22.8 98.0 91.5 11.16 0.79
≥ 6 15.2 98.4 91.2 9.73 0.86
Table 5 Sensitivity, specificity, and  likelihood ratios 
at various cut-off points of the Russian version of the PHQ-2







≥ 1 94.1 38.2 45.1 1.52 0.15
≥ 2 79.4 66.5 68.1 2.37 0.31
≥ 3 58.8 87.7 84.1 4.77 0.47
≥ 4 45.6 92.8 87.0 6.34 0.59
≥ 5 27.9 96.3 87.9 7.56 0.75
≥ 6 19.1 98.2 88.5 10.34 0.82
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The PHQ-2 Russian version correctly identified 79.4% 
of cases and 66.5% of non-cases. The positive likelihood 
ratio was 2.21 and 2.37 at this cut-off score for the Lat-
vian and Russian languages, respectively. The PHQ-2 
demonstrated moderate overall accuracy relative to the 
MINI for discriminating between cases and non-cases of 
depression, with an AUC of 0.79 for the Latvian version 
and AUC of 0.80 for the Russian version.
Discussion
The main aim of this study was to assess the validity of 
the PHQ-9 and the PHQ-2 and to establish a cut-off 
score to identify depression in the nationwide sample of 
patients attributable to Latvia visiting their GP because 
of health concerns. The screener was primarily developed 
for use in primary care settings and is the only question-
naire that has been tested in a primary care sample in 
Latvia.
Instruments that can be used in both screening and 
scaling modes have a particular advantage in that their 
weaknesses can be compensated by each other [47].
Within 18 studies performed with the PHQ-9, the 
prevalence of depression, as diagnosed by the gold-stand-
ard tests, ranged from 2.5 to 37.5% [48]. In our study, the 
point prevalence of depression was estimated at 10.2%, 
which is consistent with the findings from the other 
studies.
Despite the fact that the brief PHQ-9 is commonly used 
to screen for depression with 10 often recommended as a 
cut-off score, we found that a cut-off score of ≥ 8 on the 
PHQ-9 was the best at detecting depression in primary 
care patients in Latvia. Interestingly, the optimal cut-
off points for major depression fall in the severity range 
of 5–9, as described by Kroenke et al. [21] for the cate-
gory of patients with mild depressive symptoms. In the 
meta-analysis by Manea et al. [48], the PHQ-9 was found 
to have acceptable diagnostic properties for detecting 
depression for cut-off scores between 8 and 11. Its valid-
ity was supported by the AUC value that suggests a mod-
erate accuracy of the questionnaire.
The pooled estimates of sensitivity and specificity for a 
cut-off score of 8 reported by Manea et al. [48] were 0.82 
(95% CI 0.66–0.92) and 0.83 (95% CI 0.69–0.92), respec-
tively. In our study, the rates of sensitivity and specific-
ity for the Latvian language version were 0.75 and 0.83 
and for the Russian language version were 0.79 and 0.80, 
respectively. In a study with primary care elderly patients, 
in which the criterion validity was evaluated by admin-
istering both the PHQ-9 and the MINI, the reported 
optimal cut-off score for major depressive disorder with 
the best validity characteristics was ≥ 7 (sensitivity 0.92, 
specificity 0.78) [49]. Our study showed lower sensitiv-
ity, but higher specificity. Although, we have also studied 
primary care populations, the comparison of the stud-
ies cannot be made easily. In our study, we included all 
patients who visit their GP because of medical concerns, 
but in the study by Lamers et  al. [49], only the patients 
60 years or older diagnosed with certain chronic medical 
disorders were included.
The sensitivity of screening instruments is considered 
good when their range is 0.79–0.97 and when their speci-
ficity is 0.63–0.86 [50]. Both languages of the PHQ-9 had 
relatively low sensitivity and acceptable specificity. The 
moderate specificity of the PHQ-9 for diagnosing major 
depression can be explained because it is possible to diag-
nose the disorder without having either of the two cardi-
nal symptoms of major depression. As such, the summed 
score does not match perfectly with the MINI, which is a 
structured diagnostic interview based on DSM-IV crite-
ria [51].
The internal consistency (alpha coefficient) of the 
PHQ-9 in this study was 0.82 for the Latvian version and 
0.79 for the Russian version. For a self-report instrument 
to be reliable, it is suggested that Cronbach’s alpha be 
at least 0.70 [52]. However, it was lower than that from 
studies in the US (alpha coefficient = 0.79–0.89) [53, 54].
Recently, the PHQ-9 validation study in six primary 
care settings in Latvia was performed with a total sam-
ple size of 293 patients [42]. The estimated cut-off score 
was ≥ 10 with sensitivity 86.49% and specificity 89.36% 
for both languages. In the pilot project of the PHQ-9 vali-
dation, the PHQ-9 validity parameters were better than 
in this study. It is notable that the pilot study had con-
siderable limitations. First, there was a small number of 
subjects. Second, not all Latvian regions were covered; 
therefore, the results cannot be representative. Third, 
the study was conducted by one interviewer. This study 
was conducted with a larger sample of patients and cov-
ered all Latvian regions and was performed by four men-
tal health professionals who specialize in psychiatry and 
who were blind to the PHQ-9 and PHQ-2 results.
Our findings support the fact that an estimated cut-off 
score of 10 cannot be generalized across countries and 
populations.
The 2-question screener was sensitive for diagno-
sis of major depression when compared with the MINI 
with sensitivities of 0.90 and 0.94 for Latvian and Rus-
sian versions for thresholds of 1 or greater. Sensitivi-
ties for threshold 2 or greater comprised 0.79 for both 
language versions of the PHQ-2, and these sensitivities 
were acceptable. However, the specificities for thresh-
old 1 or greater were not acceptable, but for threshold 2 
or greater they were modest for both language versions 
of the PHQ-2: 0.65 for the Latvian version and 0.67 for 
the Russian version. At the most commonly used thresh-
old ≥ 3 [35], the sensitivity for the Latvian and Russian 
Page 6 of 8Rancans et al. Ann Gen Psychiatry  (2018) 17:33 
versions was 0.56 and 0.59 and the specificity was 0.90 
and 0.88, respectively. The finding that the score ≥ 2 was 
more successful at detecting depression is in accordance 
with similar finding reported by previous studies [55]. 
Another study to include a primary care sample (but not 
exclusively) reported a sensitivity of 0.83 and a specificity 
of 0.92 when the PHQ-2 (threshold score of 3 or higher) 
was compared with a health professional interview in 580 
patients [35]. The patients who received the reference 
standard interview had to be contacted within 48 h of the 
screening interview. In our study, the reference standard 
was provided by the telephone within 2 weeks after the 
screening phase, which may have introduced bias into 
the results. A study conducted in older patients using the 
DSM-IV as a reference standard reported a sensitivity of 
1.0 and a specificity of 0.77 for the PHQ-2 [56]. However, 
in this study, construct validity cut-off points were not 
reported. A study conducted in an outpatient clinic in 
Germany reported sensitivity and specificity was 78 and 
79%, respectively, for major depression determined by a 
PHQ-2 score of 3 or more [37]. At a threshold score of 3 
or higher and using a recognized reference standard, our 
sensitivity results for the PHQ-2 are generally not as high 
as those of other studies. This outcome can be explained 
as the result of a truly consecutive sample of patients in 
primary care, a reference standard that was adminis-
tered not immediately but within 2 weeks after screening 
or even simply chance. Another of the limitations is its 
cross-sectional design; longitudinal studies are needed to 
establish the sensitivity to change. Inclusion of currently 
diagnosed and treated patients may increase bias in stud-
ies by inflating estimates of screening accuracy [57].
The strengths of this study are that all the patients 
were from primary care and they all received the MINI 
reference standard assessment. Our study included a 
large sample size, covered all Latvian regions and was 
conducted in urban and rural settlements and is repre-
sentative to primary care in Latvia. Respondents were 
interviewed by four psychiatrists who were blind to the 
PHQ-9 estimates.
Conclusion and implications for practice
In summary, the Latvian and Russian versions of the 
PHQ-9 and PHQ-2 have moderate psychometric proper-
ties for screening for major depression in general prac-
tice with a recommended cut-off score of 8 or greater for 
the PHQ-9 and 2 or greater for the PHQ-2. For GPs who 
wish to screen their patients for depression, we suggest 
they ask patients to respond to the first 2 questions of the 
PHQ-9 (i.e., the PHQ-2); if their score is positive (if they 
score 2 or more), the patients should then complete the 
PHQ-9.
In a study on the 12-month prevalence of depression 
and healthcare utilization in the general population of 
Latvia, certain risk factors for depression were identi-
fied [13], and these factors could be useful for GPs to 
identify the target population and initiate screening 
with the PHQ-2 and PHQ-9.
In this study, established cut-off points of the PHQ-9 
and PHQ-2 together with the established risk fac-
tors for having depression in the study conducted in 
the general population [13] have been used within the 
framework of the National Research Programme, BIO-
MEDICINE, to develop diagnostic and treatment algo-
rithms for depression in primary care in Latvia.
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